The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. It was previously approved only for adults ≥60 years old.1 Two other RSV vaccines have received FDA approval: Abrysvo, a recombinant vaccine that is licensed for use in adults ≥60 years old and in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants,1 and mResvia, an mRNA vaccine recently licensed for use in...
- Iloprost (Aurlumyn) for Frostbite
- Iloperidone (Fanapt) — A New Indication for Bipolar Disorder
- Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections
- In Brief: Wezlana — An Ustekinumab Biosimilar Interchangeable with Stelara
- In Brief: Doxycycline for STI Post-Exposure Prophylaxis
- DaxibotulinumtoxinA (Daxxify) for Frown Lines (online only)
RELEASE
The FDA has approved pilocarpine 0.4% preservative-free ophthalmic solution (Qlosi – Orasis) for treatment of presbyopia in adults. Pilocarpine 1.25% ophthalmic solution (Vuity) was approved in 2021 for the same indication.1 Pilocarpine 1%, 2%, and 4% ophthalmic solutions (Isopto Carpine, and others) have been available for years for treatment of glaucoma, but local (e.g., blurry vision and instillation-site pain) and systemic (e.g., sweating and GI disturbances) adverse effects have limited their use.2
STANDARD TREATMENT — Presbyopia is an age-related condition thought to be caused by weakening of ciliary muscles or loss of lens elasticity. Corrective lenses, including glasses and contact lenses, are first-line treatments.
Pilocarpine 1.25% ophthalmic solution (2 drops administered 6 hours apart) …